3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Expanded_access
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
326
Nivolumab
289
Ipilimumab
260
Cyclophosphamide
193
aldesleukin
145
Interleukin-2
109
fludarabine phosphate
106
Temozolomide
83
Dacarbazine
81
fludarabine
80
Radiotherapy
74
trametinib
73
Vemurafenib
69
dabrafenib
66
Biopsy
65
sargramostim
50
Bevacizumab
50
Radiosurgery
49
Paclitaxel
49
Peripheral Blood Stem Cell Transplantation
48
Carboplatin
48
Magnetic Resonance Spectroscopy
47
Imiquimod
47
Aminolevulinic Acid
47
binimetinib
45
Cisplatin
45
CTLA-4 Antigen
43
cemiplimab
42
atezolizumab
41
Specimen Handling
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
pegilodecakin
×
Dermatologic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled